Gilgamesh is a serious mental health science focused, preclinical biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCE’s) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise.
We are an experienced team, with proven success in biotech exits and inventions.
Gilgamesh has a nuanced understanding of the world of psychedelic medicine which guides the creation of new chemical entities with a high probability for success. We understand the chemistry and neurobiology for ketamine analogs and psychedelic-related central nervous system compounds. They have known mechanisms of action, efficacy and demonstrated safety in long-term use in a variety of psychiatric conditions. A high probability of success is ensured by using these proven compounds as the basis for developing a portfolio of novel and patent protected new medicines.
Developing a “Better Ketamine” that is fast to clinic and exit. Treatment-Resistant Depression (adjunctive) as well as opiate use disorder. Oral formulation, composition of matter patent, robust efficacy, non-dissociative, low abuse potential, rapid onset, anti-suicidal
“Micro-Dose By Design” Therapy
ADHD, MDD with Cognitive Impairment
Safe home use, low abuse potential, subchronic use, no SSRI/SNRI AEs, rapid onset
Novel Ibogaine Analogue
Opioid Use Disorder (reduce relapse, withdrawal)
Single or periodic Tx, reduces withdrawal, reduces need for maintenance therapy, rapid onset